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Abstract: AMP-activated protein kinase (AMPK), an enzyme involved in energy homeostasis, regulates inflammatory 
responses, but its precise mechanisms are not fully understood. Recent evidence has shown that resveratrol (RES), an AMPK 
activator, reduces prostaglandin E2 production in lipopolysaccharide (LPS)-treated microglia. Here, we examined the effect of 
RES on nuclear factor kappa B (NF-κB) dependent cyclooxygenase (COX)-2 activation in LPS-treated RWA 264.7 macrophages. 
We found that treatment with RES increased AMPK activation. AMPK and acetyl CoA carboxylase phosphorylation were 
attenuated in cells treated with LPS+RES, compared to cells treated with LPS alone. RES inhibited tumor necrosis factor (TNF)-α 
and TNF receptor 1 in LPS-treated cells. Finally, RES inhibited LPS-induced NF-κB translocation into the nucleus and COX-
2 expression. Moreover, the effects of 5-aminoimidazole-4-carboxamide ribose and compound C were consistent with the 
effects of RES in LPS-treated cells. Taken together, these results suggest that the anti-inflammatory action of RES in RAW 264.7 
macrophages is dependent on AMPK activation and is associated with inhibition of the LPS-stimulated NF-κB-dependent 
COX-2 signaling pathway.
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AMPK stimulates fatty acid oxidation by phosphorylating and 
inhibiting acetyl CoA carboxylase (ACC) [4]. In particular, a 
potential role for AMPK in the suppression of inflammatory 
responses is supported by evidence obtained using an 
activator of AMPK, 5-aminoimidazole-4-carboxamide ribose 
(AICAR). AICAR reduces the synthesis of inducible nitric 
oxide synthase (NOS) by adipocytes, macrophages, and glial 
cells [5]. 
Among the immune systems that participate in host 
de  fense, macrophages are the primary cells targeted by 
lipopolysaccharide (LPS). LPS stimulates secretion of a variety 
of proinflammatory cytokines, such as interleukin (IL)-1β, 
tumor necrosis factor (TNF)-α, and IL-6. In particular, TNF-α 
plays major roles in various inflammatory diseases [6, 7]. The 
Introduction
AMP-activated protein kinase (AMPK) is an energy sensor 
that regulates energy homeostasis and metabolic stress [1]. 
AMPK is activated under conditions of glucose deprivation, 
heat shock, oxidative stress, and ischemia [2]. Once activated, 
AMPK suppresses key enzymes involved in ATP-consuming 
anabolic pathways and increases cellular ATP supply [3]. Anti-inflammatory effects of resveratrol
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activities of TNF are mediated by two receptors [8]. Most 
of the biological activities of TNF-α are mediated through 
TNF receptor (TNFR) 1, which plays a prominent role in 
anti-bacterial responses [9]. However, the role of TNFR2 is 
unclear.  
Regulation of the nuclear factor kappa B (NF-κB) trans-
cription factor is a key component of the TNF signaling 
path  way. In its inactive state, NF-κB is a cytoplasmic hete-
ro  dimer that consists of three subunits: p50, p65, and IκBα. 
In the presence of pro-inflammatory signals, IκBα is pho-
sphorylated and degraded via the proteasomal pathway, 
exposing nuclear localization signals on the p50-p65 hetero-
dimer [10]. Cyclooxygenase (COX)-2 contributes to the 
pathophysiological progression of certain human cancers 
and inflammatory disorders [11]. The COX enzyme consists 
of two isoforms designated COX-1 and COX-2. COX-1 is 
predominantly involved in physiological and regulatory 
processes, whereas COX-2 is induced in a variety of healthy 
tissues by inflammatory cytokines, growth factors, and 
oncogenes [12]. 
Resveratrol (RES), a polyphenolic compound found in 
grapes and red wine, has attracted wide attention because 
of its antioxidant and anti-inflammatory effects [13, 14]. 
Numerous studies have documented the beneficial effects of 
RES, such as cardiovascular and cancer preventive properties 
[15]. Recent evidence shows that treatment with RES 
ameliorates elevated levels of TNF-α, IL-6, and COX-2 in 
experimental diabetic neuropathy [16]. RES increases AMPK 
activity and improves insulin sensitivity [17]. In the present 
study, we demonstrated that RES reduced the expression 
of proinflammatory mediators in LPS-treated RAW 264.7 
macrophage cells in an AMPK-dependent manner. 
Materials and Methods
Reagents and antibodies
Trans-RES was obtained from ChromaDex (Irvine, CA, 
USA). AICAR and compound C (CC) were obtained from 
Toronto Research Chemicals Inc. (Toronto, ON, Canada) 
and EMD4 Biosciences (Darmstadt, Germany), respectively. 
These reagents were dissolved in dimethylsulfoxide. LPS 
was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Antibodies against p-AMPK, total AMPK, p-ACC, and total 
ACC were obtained from Cell Signaling Technology (Danvers, 
MA, USA). Antibodies against TNF-α, TNFR1 (H-5), 
TNFR2 (H-202), and lamin A (C-20) were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit 
polyclonal antibodies against NF-kB p105/p50 and COX-
2 were obtained from Abcam (Cambridge, MA, USA) and 
Cayman Chemical Co. (Ann Arbor, MI, USA), respectively. 
The antibody against β-actin was purchased from Sigma-
Aldrich.
Cell culture 
RAW 264.7 macrophage cells (ATTC, Rockville, MD, 
USA) were cultured in Dulbecco’s modified Eagle me-
dium supplemented with 10% fetal calf serum, 100 U/ml 
streptomycin, and 2 mM glutamine at 37
oC in a 5% CO2 
humidified incubator. Cells were plated at a density of 3×10
5 
cells per 60-mm dish. 
Cell stimulation
RAW 264.7 macrophages were plated at a density of 3× 
10
5 cells per 60-mm dish. The cells were rinsed with fresh 
medium and stimulated for 3-hours in the presence or 
absence of different concentrations (0.1 or 10 μΜ) of RES. 
Thereafter, RES (0.5 μM), AICAR (1 mM), and CC (10 μM) 
were added, and the cells were stimulated with LPS (50 ng/
ml) for 3-hours. 
Cytokine enzyme-linked immunosorbent assay 
(ELISA)
An ELISA was performed with a TNF-α kit (R&D Systems, 
Minneapolis, MN, USA) to measure TNF-α concentrations 
in the culture supernatants, according to the manufacturer’s 
protocol. 
Western blot analysis
Cellular extracts, cytosolic fractions, and nuclear fractions 
were prepared according to Müller et al. [18]. The protein 
concentrations in each lysate were determined using a 
bicinchoninic acid kit (Pierce, Rockford, IL, USA), according 
to the manufacturer’s protocol, using bovine serum albumin 
as the standard. Equal amounts of protein (30 µg) were 
separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes. 
The membranes were washed in Tris-buffered saline 
containing 0.5% Tween-20 (TBST) and incubated with the 
following TBST-diluted primary antibodies: rabbit anti-
p-AMPK (1 : 1,000), rabbit anti-total AMPK (1 : 1,000), 
rabbit anti-p-ACC (1 : 1,000), rabbit anti-total ACC (1 : Anat Cell Biol 2011;44:194-203 Chin-Ok Yi, et al 196
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1,000), mouse anti-TNF-α (1 : 5,00), mouse anti-TNFR1 (1 
: 500), rabbit anti-TNFR2 (1 : 500), rabbit anti-COX-2 (1 : 
1,000), and rabbit anti-NF-κB p105/p50 (1 : 1,000). Samples 
were then incubated with their corresponding secondary 
antibodies. The enhanced chemiluminescence Western blot 
analysis system (Amersham Pharmacia Biotech, Piscataway, 
NJ, USA) was used for detection. To determine the relative 
amounts of protein in each lane, the levels of β-actin (1 : 
30,000) were used as an internal control. The quantity of 
nuclear proteins was determined in parallel using anti-lamin 
A (1 : 1,000). 
Immunocytochemical analysis for NF-κB
Cells were cultured on cover glasses (MultiCell
TM plus, 
CTRL Life Science, Gwangju, Korea) and fixed with 4% 
para  formaldehyde in phosphate-buffered saline (PBS) for 
10 minutes at room temperature (RT). Permeabilization was 
performed in PBS with 0.3% Triton X-100 (PBS-T) for 10 
minutes at RT. After blocking for 30 minutes with 5% normal 
donkey serum, the cells were incubated with anti-NF-κB (1 : 
500) overnight at 4
oC. After washing with PBS, secondary 
antibody (1 : 1,000) was added for 1-hour. After washing 
with PBS, streptavidin-AlexaFluor 594 (1 : 1,000, Invitrogen, 
Carlsbad, CA, USA) was added for 1-hour. Nuclei were 
stained with DAPI (1 : 10,000, Invitrogen), and the cells were 
visualized under confocal microscopy (FV-1000, Olympus, 
Tokyo, Japan). 
Statistical analysis
Values are expressed as mean±standard error of the 
mean (SEM). Differences between groups were determined 
using analysis of variance, followed by a Bonferroni t-test 
for all pairwise multiple comparisons. P-values<0.05 were 
considered statistically significant.
Results
Effect of RES treatment on AMPK expression in LPS-
treated RAW 264.7 cells
We treated cells with various concentrations of RES to 
test the cellular toxicity of RES alone in RAW 264.7 cells 
(Fig. 1A). RES concentrations up to 0.5 μM were tolerated 
by macrophages without a significant effect on cell viability. 
Fig. 1. Effect of resveratrol (RES) treatment on AMP-activated protein kinase (AMPK) activation in RAW 264.7 cells. (A) Concentration-
dependent effects of RES on RAW 264.7 cell viability. Cells were incubated with different concentrations (0.1 or 10 mΜ) of RES for 3-h. (B) 
Western blot analysis for AMPK activation in different concentrations of RES. p-AMPK was normalized to b-actin and represented as arbitrary 
units. Data are expressed as mean±SEM of the ratio of p-AMPK protein expression for three independent experiments. P<0.05 by ANOVA. 
*P<0.005,
†P<0.001 vs. control.Anti-inflammatory effects of resveratrol
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RAW 264.7 cells were exposed to different concentrations 
(0.1 to 10 μM) of RES to determine AMPK expression in 
response to RES (Fig. 1B). Western blot analyses showed that 
AMPK phosphorylation in RAW 264.7 cells was enhanced 
significantly by treatment with RES (Fig. 1B). 
Effect of RES treatment on AMPK and ACC phos-
phorylation in LPS-treated RAW 264.7 cells
We performed Western blot analyses to evaluate the effect 
of RES on AMPK and ACC phosphorylation in LPS-treated 
RAW 264.7 cells (Fig. 2). We first investigated whether RES 
led to AMPK activation in LPS-treated cells. As shown in 
Fig. 2A, the levels of p-AMPK/AMPK expression increased 
3-hours after LPS treatment. However, RES attenuated LPS-
induced AMPK activation in RAW 264.7 cells. Additionally, 
both AICAR, a AMPK activator, and CC, an AMPK inhibitor, 
significantly attenuated LPS-induced AMPK activation in 
RAW 264.7 cells (Fig. 2A). We next investigated the effect 
of RES on ACC phosphorylation in LPS-treated RAW 264.7 
cells. In accordance with the effects on AMPK activation by 
RES, RES attenuated LPS-induced ACC phosphorylation in 
RAW 264.7 cells (Fig. 2B). 
Effect of RES treatment on TNF-α and TNFR 
expression in LPS-treated RAW 264.7 cells
First, an ELISA was used to measure TNF-α concentrations 
in the supernatant of LPS-treated cells to evaluate the effect of 
RES on cellular TNF-α production in LPS-treated RAW 264.7 
cells (Fig. 3A). TNF-α level was markedly elevated in the 
supernatants of LPS-treated cells. RES significantly inhibited 
LPS-induced TNF-α production (P<0.001). In addition, both 
AICAR and CC also significantly attenuated LPS-induced 
TNF-α expression in RAW 264.7 cells. We performed 
Western blot analyses to evaluate the inhibitory effect of RES 
Fig. 2. Effect of resveratrol (RES) treatment on AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) phosphorylation 
in lipopolysaccharide (LPS)-treated RAW 264.7 cells. Cells were incubated with 0.5 mΜ RES for 3-h, 1 mM 5-aminoimidazole-4-carboxamide 
ribose (AICAR) for 1-h, and 10 mΜ compound C (CC) for 1-h. Cells were then treated with 50 ng/ml LPS for 3­h. Cell lysates were subjected to 
Western blot analysis with p-AMPK and total AMPK (A) and p-ACC and total ACC (B) antibodies. p­AMPK or p-ACC was normalized to total 
AMPK or ACC and represented as arbitrary units, respectively. Data are expressed as mean±SEM for three independent experiments. P<0.05 by 
ANOVA. *P<0.005, 
†P<0.001 vs. control (CTL) or LPS-treated cells, respectively.Anat Cell Biol 2011;44:194-203 Chin-Ok Yi, et al 198
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on TNF-α and TNFR expression in LPS-treated RAW 264.7 
cells (Fig. 3B, C). We first investigated whether RES led to 
inhibition of TNF-α expression in LPS-treated cells. As shown 
in Fig. 3A, TNF-α expression levels increased significantly 
Fig. 3. Effect of resveratrol (RES) treatment on tumor necrosis factor (TNF)-a and TNF receptor (TNFR) expression in lipopolysaccharide 
(LPS)-treated RAW 264.7 cells. Cells were incubated with 0.5 mΜ RES for 3-h, 1 mM 5-aminoimidazole-4-carboxamide ribose (AICAR) for 
1-h, and 10 mΜ compound C (CC) for 1-h. Cells were then treated with 50 ng/ml LPS for 3-h. (A) Cell supernatant TNF-a concentrations 
measured by enzyme-linked immunosorbent assay. Cell lysates were subjected to Western blot analyses with TNF-a (B) and TNFR (C) antibodies, 
respectively. TNF-a and TNFR1 were normalized to b-actin and represented as arbitrary units. Data are expressed as mean±SEM for three 
independent experiments. P<0.05 by ANOVA. *P<0.005, 
†P<0.001 vs. the respective control (CTL) or LPS-treated cells, respectively.Anti-inflammatory effects of resveratrol
http://dx.doi.org/10.5115/acb.2011.44.3.194
Anat Cell Biol 2011;44:194-203 199
www.acbjournal.org
3-hours after LPS treatment. However, RES attenuated LPS-
induced TNF-α expression. Moreover, both AICAR and CC 
significantly attenuated LPS-induced TNF-α expression in 
RAW 264.7 cells (Fig. 3B). We next investigated the effect of 
Fig. 4. Effect of resveratrol (RES) treatment on nuclear factor kB (NF-kB) translocation in lipopolysaccharide (LPS)-treated RAW 264.7 cells. 
(A) Representative photomicrographs of immunolabeling for NF-kB (red) and nuclear counterstaining with DAPI (blue) in control (CTL), LPS, 
LPS+RES, LPS+5-aminoimidazole-4-carboxamide ribose (AICAR), and LPS+compound C (CC)-treated RAW 264.7 cells. LPS treatment 
induced increased colocalization of NF-kB and DAPI (purple) in LPS-treated cells. However, RES treatment reduced NF-kB translocation, as 
shown by decreased colocalization with DAPI. Arrows indicate translocation from the cytoplasm to the nucleus. Scale bar=100 mm. (B) Nuclear 
translocation of cytoplasmic NF-kB from each group was assessed by Western blotting. (C) Quantitative analysis of NF-kB levels calculated from 
Western blots. Cytoplasmic (cyto) or nuclear (nu) NF-kB was normalized to b-actin or lamin A and represented as arbitrary units, respectively. 
Data are expressed as mean±SEM for three independent experiments. P<0.05 by ANOVA. *P<0.05, 
†P<0.001 vs. the respective control (CTL) or 
LPS-treated cells, respectively.Anat Cell Biol 2011;44:194-203 Chin-Ok Yi, et al 200
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RES on TNFR1 and TNFR2 expression in LPS-treated RAW 
264.7 cells. In particular, the level of TNFR1 protein was 
reduced by RES, as well as by AICAR and CC. However, no 
change in TNFR2 expression was observed in LPS-treated 
RAW 264.7 cells (Fig. 3C). 
Effect of RES treatment on NF-κB translocation in 
LPS-treated RAW 264.7 cells
To confirm the effect of RES treatment on NF-κB trans-
location in LPS-treated RAW 264.7 cells, we performed 
immunocytochemistry for NF-κB, stained nuclei with DAPI, 
and conducted a Western blot analysis for NF-κB nuclear 
translocation (Fig. 4). We found nuclear co-staining for 
NF-κB and DAPI in LPS-treated RAW 264.7 cells but not 
in control cells (Fig. 4A). However, RES, AICAR, and CC 
treatment inhibited NF-κB translocation into the nucleus 
of LPS-treated RAW 264.7 cells. We further examined ex-
pression of the NF-κB p50 subunit in the cytoplasmic and 
nuclear extracts from each group (Fig. 4B). RES inhibited NF-
κB nuclear translocation in LPS-treated RAW 264.7 cells (Fig. 
4C). In addition to RES, both AICAR and CC inhibited NF-
κB translocation from the cytoplasm into the nucleus.
Effect of RES treatment on COX-2 expression in LPS-
treated RAW 264.7 cells
We performed Western blot analyses for COX-2 to explore 
whether LPS-induced COX-2 expression in RAW 264.7 
cells is altered by RES treatment (Fig. 5A). COX-2 protein 
expression increased significantly in LPS-treated RAW 264.7 
cells. However, in accordance with the inhibitory effect 
of both AICAR and CC, RES significantly inhibited LPS-
induced COX-2 expression 3-hours after LPS treatment (Fig. 
5B).
Discussion
We demonstrated that RES-induced AMPK preactivation 
significantly decreased pro-inflammatory cytokine TNF-α 
expression and NF-κB-mediated COX-2 expression in LPS-
treated RAW 264.7 cells. Furthermore, treatment with an 
AMPK activator or inhibitor also decreased TNF-α and 
TNFR1-mediated NF-κB-dependent COX-2 expression in 
LPS-treated RAW 264.7 cells. Some reports have indicated 
the ability of AMPK to inhibit inflammation of macrophages, 
microglia, and astrocytes by inhibiting TNF-α and COX-2. In 
addition to the anti-inflammatory effects of AMPK activators 
such as RES or AICAR, the most striking finding is that CC, 
a direct AMPK inhibitor, exerted anti-inflammatory effects 
in LPS-treated RAW264.7 cells similar to those of AMPK 
activators. Thus, we would like to emphasize the importance 
of the dual effect of AMPK in macrophage-oriented inflam-
mation.
RES is a major component of the polyphenols present 
in grapes and red wine. RES was originally identified as 
the active ingredient of an oriental herb used to treat se-
veral diseases including dermatitis, fever, hyperlipidemia, 
arteriosclerosis, and inflammation [19]. RES is also thought 
Fig. 5. Effect of resveratrol (RES) treatment on cyclooxygenase 
(COX)-2 expression in lipopolysaccharide (LPS)-treated RAW 
264.7 cells. (A) Cells were incubated with 0.5 mΜ RES for 3-h, 1 mM 
5-aminoimidazole-4-carboxamide ribose (AICAR) for 1-h, and 10 
mΜ compound C (CC) for 1-h. Cells were then treated with 50 ng/
ml LPS for 3-h. Cell lysates were subjected to Western blot analysis 
with a COX-2 antibody. (B) Quantitative analysis of COX-2 levels 
calculated from Western blots. COX-2 was normalized to b-actin and 
represented as arbitrary units. Data are expressed as mean±SEM for 
three independent experiments. P<0.05 by ANOVA. *P<0.001 vs. the 
respective control (CTL) or LPS-treated cells, respectively.Anti-inflammatory effects of resveratrol
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to protect against myocardial ischemia and to be a major 
contributor to the French paradox [13, 20]. This paradox is 
characterized by a lower incidence of coronary heart disease 
among regular drinkers of red wine, particularly in the south 
of France. Indeed, evidence obtained from several animal 
model studies suggests that RES decreases arachidonic 
acid release and COX-2 induction in mouse peritoneal 
macrophages stimulated with LPS [21]. 
AMPK was identified by its ability to phosphorylate and 
inhibit key enzymes involved in biosynthetic pathways, such 
as ACC (fatty acid synthesis) and 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (cholesterol biosynthesis) [22]. Because 
cholesterol metabolites attenuate inflammatory responses [23], 
we examined the possible role of AMPK after RES treatment 
in LPS-stimulated macrophages. In general, inflammatory 
stimuli induce the production of reactive oxygen species and 
increase intracellular calcium concentration [24], leading to 
the activation of AMPK-activating kinases [25]. As shown 
in Fig. 2, LPS treatment significantly increased AMPK 
phosphorylation; however, pretreatment with RES or AICAR 
significantly inhibited LPS-induced AMPK phosphorylation. 
Similarly, an increase in the phosphorylation of ACC, a 
downstream target of AMPK, was observed and was a good 
correlate of AMPK activation. Furthermore, some reports 
have been contradictory about the effect of AMPK on anti-
apoptotic activity or cell death. Long-term stimulation of 
AMPK with AICAR prevents apoptosis in astrocytes [26]. 
However, despite the possible protective effects, several 
reports have shown that AMPK promotes cell death in a 
variety of cell types, including neurons, and that inhibiting 
AMPK protects cells from ATP depletion-induced cell death 
following exposure to various stressors [27, 28]. In the present 
study, we identified AMPK as a potent counter-regulator of 
macrophage inflammatory function. Our data show that RES 
concentrations up to 0.5 μM were tolerated by macrophages 
without a significant effect on cell viability. AMPK expression 
increased significantly with 0.5 μM RES. This result indicates 
that RES pretreatment provides a preconditioning state for 
a decrease in the ATP to AMP ratio and then counteracts 
the LPS-activated AMPK phosphorylation in macrophage 
cells. In contrast, sustained AMPK activation may aggravate 
inflammation after cellular stresses or insults. We also found 
that CC may have an ambivalent effect on the inflammatory 
response in LPS-treated RAW 264.7 macrophages as an 
AMPK inhibitor. Thus, we suggest that modest preactivation 
of AMPK by RES or inhibition of AMPK by CC may induce 
positive effects such as an anti-inflammatory effect.
TNF-α is a potent proinflammatory cytokine released 
primarily from stimulated macrophages. Many aspects 
of tissue injury following acute or chronic inflammatory 
responses can be directly attributed to the concomitant 
induction of TNF biosynthesis and release [29]. All known 
responses to TNF are triggered by binding to one of two 
distinct receptors, TNFR1 or TNFR2, which are differentially 
regulated on various cell types in normal and diseased 
tissues [30]. Based on cell culture and animal studies of each 
receptor in knockout mice, proinflammatory and cell death 
pathways, which are activated by TNF, are mediated primarily 
through TNFR1 [31]. The effect of TNFR2 signaling is less 
characterized. In the present study, we clearly demonstrated 
that RES-induced AMPK preactivation can be mediated by 
inhibiting TNF-α through TNFR1 expression caused by LPS 
stimulation. This result is consistent with previous evidence 
that AICAR suppresses LPS-induced TNF-α secretion in 
RAW 264.7 cells [32]. Thus, our data indicate that RES may 
inhibit inflammatory mediators by preactivating AMPK. 
The most striking finding of our study was that CC, a 
direct AMPK inhibitor, had anti-inflammatory properties 
similar to those of RES and AICAR. In particular, we 
demonstrated that CC attenuated TNF-α protein expression 
in LPS-treated RAW 264.7 cells to an equivalent or greater 
extent than RES or AICAR. This result is consistent with 
a previous study showing that CC down-regulates IL-1β, 
IL-6, and TNF-α release in LPS-stimulated microglia [33]. 
However, it does not support their observation that CC did 
not alter the p-AMPK/AMPK ratio in either LPS-stimulated 
or non-stimulated microglia. A recent study demonstrated 
that the inhibitory effect of berberine on iNOS and COX-2 
expression was abolished by CC-induced AMPK inhibition 
[34]. This supports our result that CC reduced levels of 
TNF-α and COX-2 expression in LPS-stimulated RAW 264.7 
cells. Our results showed that the p-AMPK/AMPK ratio in 
LPS+CC-treated cells decreased significantly compared that 
in LPS+RES-treated cells (Fig. 2A). This result indicates that 
CC could act as direct AMPK inhibitor and counteract LPS-
induced AMPK activation. In particular, we demonstrated 
that both activators and inhibitors of AMPK attenuated LPS-
induced AMPK phosphorylation in RAW 264.7 cells. Our 
results may suggest that an AMPK inhibitor could act as a 
direct AMPK inhibitor. In contrast, AMPK activators could 
offer a preventive condition against insult-induced changes 
in cellular energy homeostasis and counteract LPS-induced Anat Cell Biol 2011;44:194-203 Chin-Ok Yi, et al 202
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AMPK activation. Thus, we suggest that modest preactivation 
of AMPK may contribute to anti-inflammatory properties 
similar to those of an AMPK inhibitor. Although pretreatment 
with CC reduced LPS-induced ACC phosphorylation, the 
degree of reduction in ACC phosphorylation was different 
compared to AMPK phosphorylation. This difference in-
dicates that the relative expression level of AMPK or ACC 
phosphorylation in LPS-treated cells was different compared 
to that in controls. 
Several groups have suggested that AMPK serves as an 
anti-inflammatory target. For example, AMPK activation 
by AICAR downregulates LPS-mediated induction of the 
proinflammatory cytokine iNOS and NO production in 
rat glial cells by inhibiting NF-κB nuclear translocation 
[5]. Metformin also attenuates monocyte infiltration in an 
experimental model of multiple sclerosis [35]. In fact, the 
NF-κB cascade is considered one of the major players in the 
inflammatory response. NF-κB activation results in elevated 
levels of inflammatory mediators. COX-2 activity has also 
been correlated with inflammatory damage. In experimental 
diabetic neuropathy, RES treatment attenuates elevated levels 
of p65, IκB-α, and COX-2 in diabetic rats and protects against 
diabetic neuropathy [16]. Recent reports have shown that 
berberine activates AMPK in adipocytes, endothelial cells, 
macrophages, and the liver [36, 37]. Berberine has been used 
to treat type 2 diabetes in China [38]. The anti-inflammatory 
effect of berberine in BV-2 microglia is consistent with 
our results, indicating that RES suppresses inflammation 
responses through AMPK activation in LPS-stimulated 
macrophages. 
In conclusion, our results demonstrate that RES-in-
duced AMPK preactivation had a therapeutic effect in 
LPS-treated RAW 264.7 cells, and that this effect was medi-
ated by activating the AMPK/ACC signaling pathway. In 
particular, we demonstrated that RES-induced AMPK pre-
ac  tivation decreased rather than increased LPS-induced 
AMPK expression in RAW 264.7 cells. Our results show 
that RES significantly attenuated TNF-α-mediated TNFR1 
expression, NF-κB translocation, and COX-2, similar to 
the anti-inflammatory effects of AICAR. In addition to the 
anti-inflammatory effects of AMPK activators such as RES 
or AICAR, the most striking finding was that CC, a direct 
AMPK inhibitor, had anti-inflammatory properties in LPS-
treated RAW264.7 cells similar to those of AMPK activators. 
Thus, our results indicate that RES may play an important 
role in anti-inflammation, and new targets for the AMPK/
ACC signaling pathway could be used as effective therapies 
for inflammatory diseases such as diabetes mellitus and 
neurodegenerative diseases.  
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